Host |
Rat |
Klon |
LOB12 |
Format |
Purified |
Methode |
FL |
Verdünnung |
1:10 - 1:50 |
Isotyp |
Rat IgG2a |
Verdünnung |
Murine CD137 human Fc fusion protein |
4-1 BB (CD137)
|
Zytomed Systems |
LOB12 |
250 µg |
Purified |
RUO |
600-0007 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate Carcinoma, Brain |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from N-terminus of human 14-3-3 beta |
Lokalisation |
Cytoplasm |
14-3-3 Beta Protein (NT)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-2924 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
P, WB |
Verdünnung |
10 µg/mL (P) |
Isotyp |
Rabbit IgG |
Verdünnung |
A 15 amino acid peptide located near human Adiponectin carboxy-terminus |
Acrp30 (Adiponectin)
|
Zytomed Systems |
polyclonal |
100 µg |
Purified |
RUO |
601-0027 |
-
|
Host |
Mouse |
Klon |
57 |
Format |
Purified |
Methode |
P, EL |
Vorbehandlung |
Trpysin or Pronase |
Verdünnung |
1:100 - 1:200 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Keyhole Limpet Haemocyanin conjugated human ACTH (1-17) |
ACTH
|
Zytomed Systems |
57 |
1 mg |
Purified |
RUO |
601-0029 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, P, EL |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the amino acids 1-24 of ACTH conjugated to Keyhole limpet Haemocyanin |
ACTH
|
Zytomed Systems |
polyclonal |
500 µl |
Purified |
RUO |
601-0030 |
-
|
Host |
Mouse |
Klon |
AH26 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
optional |
Positivkontrolle |
Pituitary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to aa 1-24 from the N-terminus fo human ACTH |
Lokalisation |
Cytoplasm |
ACTH
|
Diagnostic Biosystems |
AH26 |
1 ml |
Concentrate |
CE/IVD |
MOB244 |
-
|
Host |
Mouse |
Klon |
AH26 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
optional |
Positivkontrolle |
Pituitary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to aa 1-24 from the N-terminus fo human ACTH |
Lokalisation |
Cytoplasm |
ACTH
|
Diagnostic Biosystems |
AH26 |
0.1 ml |
Concentrate |
CE/IVD |
MOB244-01 |
-
|
Host |
Mouse |
Klon |
AH26 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
optional |
Positivkontrolle |
Pituitary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to aa 1-24 from the N-terminus fo human ACTH |
Lokalisation |
Cytoplasm |
ACTH
|
Diagnostic Biosystems |
AH26 |
0.5 ml |
Concentrate |
CE/IVD |
MOB244-05 |
-
|
Host |
Mouse |
Klon |
ZM98 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide corresponding to aa25-39 of human ACTH (NGAEDESAEAFPLEF) |
Lokalisation |
Cytoplasm |
ACTH
|
Zeta Corporation |
ZM98 |
1 ml |
Concentrate |
CE/IVD |
Z2408ML |
-
|
Host |
Mouse |
Klon |
ZM98 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide corresponding to aa25-39 of human ACTH (NGAEDESAEAFPLEF) |
Lokalisation |
Cytoplasm |
ACTH
|
Zeta Corporation |
ZM98 |
7 ml |
Ready-to-use |
CE/IVD |
Z2408MP |
-
|
Host |
Mouse |
Klon |
ZM98 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide corresponding to aa25-39 of human ACTH (NGAEDESAEAFPLEF) |
Lokalisation |
Cytoplasm |
ACTH
|
Zeta Corporation |
ZM98 |
0.5 ml |
Concentrate |
CE/IVD |
Z2408MS |
-
|
Host |
Mouse |
Klon |
ZM98 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pituitary. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide corresponding to aa25-39 of human ACTH (NGAEDESAEAFPLEF) |
Lokalisation |
Cytoplasm |
ACTH
|
Zeta Corporation |
ZM98 |
0.1 ml |
Concentrate |
CE/IVD |
Z2408MT |
-
|
Host |
Mouse |
Klon |
HHF35 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
optional |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
SDS extracted protein from human myocardium |
Lokalisation |
Cytoplasm |
Actin (Muscle)
|
Diagnostic Biosystems |
HHF35 |
1 ml |
Concentrate |
CE/IVD |
MOB002 |
-
|
Host |
Mouse |
Klon |
HHF35 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
optional |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
SDS extracted protein from human myocardium |
Lokalisation |
Cytoplasm |
Actin (Muscle)
|
Diagnostic Biosystems |
HHF35 |
0.1 ml |
Concentrate |
CE/IVD |
MOB002-01 |
-
|
Host |
Mouse |
Klon |
HHF35 |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
optional |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
SDS extracted protein from human myocardium |
Lokalisation |
Cytoplasm |
Actin (Muscle)
|
Diagnostic Biosystems |
HHF35 |
0.5 ml |
Concentrate |
CE/IVD |
MOB002-05 |
-
|
Host |
Mouse |
Klon |
HHF35 |
Format |
Ready-to-use |
Methode |
F, P, WB |
Vorbehandlung |
optional |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
SDS extracted protein from human myocardium |
Lokalisation |
Cytoplasm |
Actin (Muscle)
|
Diagnostic Biosystems |
HHF35 |
6 ml |
Ready-to-use |
CE/IVD |
PDM002 |
-
|
Host |
Mouse |
Klon |
5C5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
Actin alpha (Sarcomeric)
|
Diagnostic Biosystems |
5C5 |
1 ml |
Concentrate |
CE/IVD |
MOB128 |
-
|
Host |
Mouse |
Klon |
5C5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
Actin alpha (Sarcomeric)
|
Diagnostic Biosystems |
5C5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB128-01 |
-
|
Host |
Mouse |
Klon |
5C5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
Actin alpha (Sarcomeric)
|
Diagnostic Biosystems |
5C5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB128-05 |
-
|
Host |
Mouse |
Klon |
5C5 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
- |
Isotyp |
Mouse IgM |
Lokalisation |
Cytoplasm |
Actin alpha (Sarcomeric)
|
Diagnostic Biosystems |
5C5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM099 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
- |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the N-terminus of human alpha smooth muscle isoform of actin |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Zytomed Systems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
501-2462 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
- |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the N-terminus of human alpha smooth muscle isoform of actin |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-2464 |
-
|
Host |
Rabbit |
Klon |
SP171 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
- |
Positivkontrolle |
Colon |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of human SMA protein |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Zytomed Systems |
SP171 |
0.5 ml |
Concentrate |
RUO |
501-4712 |
-
|
Host |
Rabbit |
Klon |
SP171 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
- |
Positivkontrolle |
Colon |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of human SMA protein |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Zytomed Systems |
SP171 |
1 ml |
Concentrate |
RUO |
501-4714 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Diagnostic Biosystems |
1A4 |
1 ml |
Concentrate |
CE/IVD |
MOB001 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Diagnostic Biosystems |
1A4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB001-01 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Diagnostic Biosystems |
1A4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB001-05 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Diagnostic Biosystems |
1A4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM003 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Leiomyosarcom |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Actin alpha (Smooth Muscle)
|
Diagnostic Biosystems |
1A4 |
25 ml |
Ready-to-use |
CE/IVD |
PDM003-25 |
-
|
Host |
Rabbit |
Klon |
SP124 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of human actin-beta protein |
Lokalisation |
Cytoplasm |
Actin beta
|
Zytomed Systems |
SP124 |
0.5 ml |
Concentrate |
RUO |
501-4242 |
-
|
Host |
Rabbit |
Klon |
SP124 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of human actin-beta protein |
Lokalisation |
Cytoplasm |
Actin beta
|
Zytomed Systems |
SP124 |
1 ml |
Concentrate |
RUO |
501-4244 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Leiomyosarcom |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
N-terminal human beta actin |
Lokalisation |
Cytoplasm, Cell Membrane |
Actin beta
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
501-4554 |
-
|
Host |
Mouse |
Klon |
EA-53 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Actinin alpha
|
Diagnostic Biosystems |
EA-53 |
1 ml |
Concentrate |
CE/IVD |
MOB227 |
-
|
Host |
Mouse |
Klon |
EA-53 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Actinin alpha
|
Diagnostic Biosystems |
EA-53 |
0.1 ml |
Concentrate |
CE/IVD |
MOB227-01 |
-
|
Host |
Mouse |
Klon |
EA-53 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Actinin alpha
|
Diagnostic Biosystems |
EA-53 |
0.5 ml |
Concentrate |
CE/IVD |
MOB227-05 |
-
|
Host |
Mouse |
Klon |
20/11+2/6 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Adenovirus infected tissue |
Verdünnung |
1:25 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Adenovirus |
Lokalisation |
Virus |
Adenovirus
|
Zeta Corporation |
20/11+2/6 |
1ml |
Concentrate |
CE/IVD |
Z2566ML |
-
|
Host |
Mouse |
Klon |
20/11+2/6 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Adenovirus infected tissue |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Adenovirus |
Lokalisation |
Virus |
Adenovirus
|
Zeta Corporation |
20/11+2/6 |
7 ml |
Ready-to-use |
CE/IVD |
Z2566MP |
-
|
Host |
Mouse |
Klon |
20/11+2/6 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Adenovirus infected tissue |
Verdünnung |
1:25 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Adenovirus |
Lokalisation |
Virus |
Adenovirus
|
Zeta Corporation |
20/11+2/6 |
0.5 ml |
Concentrate |
CE/IVD |
Z2566MS |
-
|
Host |
Mouse |
Klon |
20/11+2/6 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Adenovirus infected tissue |
Verdünnung |
1:25 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Adenovirus |
Lokalisation |
Virus |
Adenovirus
|
Zeta Corporation |
20/11+2/6 |
0.1 ml |
Concentrate |
CE/IVD |
Z2566MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane and cytoplasm |
Adipophilin
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI3138A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane and cytoplasm |
Adipophilin
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3138AA |
-
|
Host |
Mouse |
Klon |
DBM15.60 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Adrenal gland |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b kappa |
Verdünnung |
Recombinant human Adipophilin protein fragment |
Lokalisation |
Cytoplasm |
Adipophilin
|
Diagnostic Biosystems |
DBM15.60 |
1 ml |
Concentrate |
CE/IVD |
MOB534 |
-
|
Host |
Mouse |
Klon |
DBM15.60 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Adrenal gland |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b kappa |
Verdünnung |
Recombinant human Adipophilin protein fragment. |
Lokalisation |
Cytoplasm |
Adipophilin
|
Diagnostic Biosystems |
DBM15.60 |
0.1 ml |
Concentrate |
CE/IVD |
MOB534-01 |
-
|
Host |
Mouse |
Klon |
DBM15.60 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Adrenal gland |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2b kappa |
Verdünnung |
Recombinant human Adipophilin protein fragment |
Lokalisation |
Cytoplasm |
Adipophilin
|
Diagnostic Biosystems |
DBM15.60 |
0.5 ml |
Concentrate |
CE/IVD |
MOB534-05 |
-
|
Host |
Mouse |
Klon |
DBM15.60 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Adrenal gland |
Verdünnung |
- |
Isotyp |
IgG2b kappa |
Verdünnung |
Recombinant human Adipophilin protein fragment |
Lokalisation |
Cytoplasm |
Adipophilin
|
Diagnostic Biosystems |
DBM15.60 |
6 ml |
Ready-to-use |
CE/IVD |
PDM534 |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Fetal liver or hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a / kappa |
Verdünnung |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Lokalisation |
Cytoplasm |
AFP
|
Zeta Corporation |
C3 |
1 ml |
Concentrate |
CE/IVD |
Z2623ML |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Fetal liver or hepatocellular carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2a / kappa |
Verdünnung |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Lokalisation |
Cytoplasm |
AFP
|
Zeta Corporation |
C3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2623MP |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Fetal liver or hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a / kappa |
Verdünnung |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Lokalisation |
Cytoplasm |
AFP
|
Zeta Corporation |
C3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2623MS |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Fetal liver or hepatocellular carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a / kappa |
Verdünnung |
Alpha fetoprotein (AFP) purified from serum of a hepatoma patient |
Lokalisation |
Cytoplasm |
AFP
|
Zeta Corporation |
C3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2623MT |
-
|
Host |
Rabbit |
Klon |
SP154 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human AFP |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Zytomed Systems |
SP154 |
0.5 ml |
Concentrate |
RUO |
501-4542 |
-
|